Gedea´s ambition is to develop the first antibiotic-free treatment that both treats and prevents bacterial vaginosis. pHyph is a vaginal tablet that has shown an excellent medical effect.
pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.
Bacterial vaginosis is a recurring problem that affects women around the world.
In our most recently concluded trial, 90% of patients had a symptom reduction. At day 35 throughout the 4 month follow-up period, recurrence was substantially lower after treatment with pHyph compared to the antibiotic rescue-treated patients.
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Gedea Biotech has completed the recruitment for NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.